Aegerion Pharmaceuticals, Inc.
) reported fourth quarter 2012 net loss per share of 86 cents,
wider than the Zacks Consensus Estimate of a loss of 62 cents and
the year-ago loss of 61 cents.
Net loss for the full-year 2012 was $2.64 compared with a net
loss of $2.03 in 2011.
Aegerion did not generate any revenues in 2012.
In the fourth quarter of 2012, research and development
expenses were $8.6 million, compared with $8.4 million in the
year-ago quarter. Expenses were driven by production validation
runs and increased headcount in support of Aegerion's regulatory
and medical affairs activities.
Selling, general and administrative expenses soared 204.7%
year over year to $13.1 million, mainly due to administrative
expenses and costs related to increased headcount for the launch
The launch of Juxtapid is in progress with the company set to
achieve the earlier guidance of 250-300 patients worldwide by the
end of 2013.
Juxtapid was approved by the US Food and Drug Administration
(FDA) in Dec 2012. It gained approval for the treatment of
patients suffering from homozygous familial hypercholesterolemia
(HoFH) as an adjunct to a low-fat diet and other lipid-lowering
therapies, including LDL apheresis where available, to reduce
low-density lipoprotein cholesterol (LDL-C), total cholesterol
(TC), apolipoprotein B (apo B) and non-high-density-lipoprotein
cholesterol (non-HDL) in patients with HoFH.
Juxtapid could gain EU approval in mid-2013.
Total operating expenses, including share-based compensation,
are expected in the range of $75 million to $85 million in
Aegerion expects net revenues in the range $15 million to $25
million in 2013. The company expects 250 to 300 patients to be on
Juxtapid therapy worldwide in 2013.
Aegerion expects to generate an annualized worldwide net
revenue run rate of $100 million in the second half of 2014 and
also achieve breakeven cash flow from operations.
We are encouraged with the progress on the launch of Juxtapid. We
Isis Pharmaceuticals Inc.
) is also looking to enter the market with its HoFH candidate,
Kynamro, approved in the US in Jan 2013.
The stock carries a Zacks #3 Rank (Hold). Currently, companies
) look more attractive with a Zacks Rank #2 (Buy).
AEGERION PHARMA (AEGR): Free Stock Analysis
AGENUS INC (AGEN): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis
To read this article on Zacks.com click here.